Viewing nowCombinationJadis Duo Tablets 5/500 mg (Empagliflozin, Metformin)
Empagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 202201353 · Approved 2022.04.04 · Insurance code 657808280
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used to effectively improve blood sugar levels in adults with type 2 diabetes who cannot achieve proper control with diet and exercise alone, through the combined action of empagliflozin and metformin. It is particularly suitable for patients whose blood sugar is not sufficiently controlled, and can also be administered to patients with type 2 diabetes who have cardiovascular disease. However, risks associated with cardiovascular events should be referred to professional guidelines. This drug contributes to safely controlling blood sugar and assisting in diabetes management.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This drug can cause severe lactic acidosis, so it should not be used in patients with poor kidney function, severe infection, or dehydration. Additionally, caution should be taken as there is a risk of hypoglycemia when taken with insulin or sulfonylureas. This drug is not administered to patients with moderate to severe kidney dysfunction or in situations where acute kidney injury is anticipated. Patients with acute heart disease, heart failure, liver dysfunction, pregnant or breastfeeding women should also avoid this drug. Regular kidney function tests should be conducted before and during use of this drug, especially in elderly patients or those with diminished kidney function. This drug can influence body fluid volume and carries a risk of dehydration or low blood pressure, so caution should be exercised in patients with dehydration symptoms or low blood pressure. During treatment, patients must be alert to symptoms of hypoglycemia resulting from excessively low blood sugar, and should be cautious about irregular meals or excessive exercise as these may increase risks. Genital and urinary infections may occur, so if related symptoms arise, consultation with a doctor should be sought immediately. Women who are pregnant or planning to become pregnant should not use this drug, and breastfeeding women are also advised to avoid it. If surgery is planned or diagnostic tests using iodinated contrast agents are to be conducted, this drug should be temporarily discontinued, and it should only be resumed after confirming that kidney function is normal. In cases of overdose, serious side effects such as lactic acidosis may occur, so immediate medical attention is required. This drug has not been established as safe and effective in children, so it should not be used in individuals under 18 years of age. Elderly patients carry a higher risk of kidney dysfunction and fluid loss, thus requiring dosage adjustments and monitoring of kidney function. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid it while taking this medication. During the use of this drug, it is important to consult with a healthcare professional if abnormal symptoms occur, and to regularly check for any side effects.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to avoid exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Taking these precautions will help maintain the drug's effectiveness.
Orange-yellow, biconvex, oval film-coated tablet
10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 60 tablets/box [10 tablets/PTP x 6], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.